Advertisement

Journal of Bone and Mineral Metabolism

, Volume 36, Issue 6, pp 734–740 | Cite as

Bisphosphonates prevent age-related weight loss in Japanese postmenopausal women

  • Tomohiko Urano
  • Masataka Shiraki
  • Tatsuhiko Kuroda
  • Shiro Tanaka
  • Fumihiko Urano
  • Kazuhiro Uenishi
  • Satoshi Inoue
Original Article

Abstract

Decline of body weight with aging is a major risk factor for frailty, osteoporosis and fracture, suggesting that treatment for osteoporosis may affect body composition. Recently, we have shown that 5-year treatment with raloxifene prevented age-related weight loss, suggesting some other drugs for osteoporosis may also prevent a decrease in body weight with aging. The present study aimed to identify the relationship between bisphosphonate treatment and body composition markers. We measured bone mineral density (BMD), body composition, and bone remodeling markers in 551 Japanese postmenopausal women with bisphosphonate treatment, which included risedronate or alendronate treatment (BP-treatment group; N = 193) and without treatment by any osteoporosis drug (no-treatment group; N = 358) for 4–7 years (mean observation periods; 5.5 years) and analyzed the relationship of these with BMD, body mass index (BMI), body weight, and biochemical markers. The mean (SD) age of the participants was 68.6 (9.8) years in the BP-treatment group and 63.7 (10.6) years in the no-treatment group. Percent changes in body weight and BMI were significantly different between the BP-treatment and no-treatment groups (P < 0.01 and P < 0.01, respectively). In multiple linear regression analysis, bisphosphonate treatment was a significant independent determinant of percent changes in body weight and BMI (P < 0.01 and P = 0.01, respectively). Long-term use of bisphosphonates prevented reductions in BMI and body weight, usually observed in elderly women. Our results suggest that bisphosphonate treatment not only reduces the risk for incident osteoporotic fractures but also for frailty in the elderly.

Keywords

Bisphosphonates Body weight Body mass index Long-term treatment 

Notes

Acknowledgements

This work was supported by grants from the Japan Society for the Promotion of Science (25293214 and 16K09796), the Ministry of Culture, Education, Sports, Science and Technology of Japan, and Japan Osteoporosis Foundation. We appreciate all the volunteers for precious clinical data and samples.

Compliance with ethical standards

Conflict of interest

Tatsuhiko Kuroda is an employee of Asahi Kasei. Tomohiko Urano, Masataka Shiraki, Shiro Tanaka, Fumihiko Urano, Kazuhiro Uenishi and Satoshi Inoue declare that they have no conflict of interest.

References

  1. 1.
    Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K (2013) Frailty in elderly people. Lancet 381:752–762CrossRefGoogle Scholar
  2. 2.
    Xue Q-L (2012) The frailty syndrome: definition and natural history. Clin Geriatr Med 27:1–15CrossRefGoogle Scholar
  3. 3.
    Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, Seeman T, Tracy R, Kop WJ, Burke G, McBurnie MA, Cardiovascular Health Study Collaborative Research Group (2001) Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 56:M146–M156CrossRefGoogle Scholar
  4. 4.
    Urano T, Shiraki M, Kuroda T, Tanaka S, Uenishi K, Inoue S (2017) Preventive effects of raloxifene treatment on age related weight loss in postmenopausal women. J Bone Miner Metab 35:108–113CrossRefGoogle Scholar
  5. 5.
    Sambrook P, Cooper C (2006) Osteoporosis. Lancet 367:2010–2018CrossRefGoogle Scholar
  6. 6.
    Maraka S, Kennel KA (2015) Bisphosphonates for the prevention and treatment of osteoporosis. BMJ 351:h3783CrossRefGoogle Scholar
  7. 7.
    Bolland MJ, Grey AB, Gamble GD, Reid IR (2010) Effect of osteoporosis treatment on mortality: a meta-analysis. J Clin Endocrinol Metab 95:1174–1181CrossRefGoogle Scholar
  8. 8.
    Center JR, Bliuc D, Nguyen ND, Nguyen TV, Eisman JA (2011) Osteoporosis medication and reduced mortality risk in elderly women and men. J Clin Endocrinol Metab 96:1006–1014CrossRefGoogle Scholar
  9. 9.
    Lee P, Ng C, Slattery A, Nair P, Eisman JA, Center JR (2016) Preadmission bisphosphonate and mortality in critically ill patients. J Clin Endocrinol Metab 101:1945–1953CrossRefGoogle Scholar
  10. 10.
    Shiraki M, Kuroda T, Shiraki Y, Aoki C, Sasaki K, Tanaka S (2010) Effects of bone mineral density of the lumbar spine and prevalent vertebral fractures on the risk of immobility. Osteoporos Int 21:1545–1551CrossRefGoogle Scholar
  11. 11.
    Tanaka S, Uenishi K, Yamazaki Y, Kuroda T, Shiraki M (2014) Low calcium intake is associated with high plasma homocysteine levels in postmenopausal women. J Bone Miner Metab 32:317–323CrossRefGoogle Scholar
  12. 12.
    Uenishi K, Ishida H, Nakamura K (2008) Development of a simple food frequency questionnaire to estimate intakes of calcium and other nutrients for the prevention and management of osteoporosis. J Nutr Sci Vitaminol (Tokyo) 54:25–29CrossRefGoogle Scholar
  13. 13.
    Orimo H, Hayashi Y, Fukunaga M, Sone T, Fujiwara S, Shiraki M, Kushida K, Miyamoto S, Soen S, Nishimura J, Oh-Hashi Y, Hosoi T, Gorai I, Tanaka H, Igai T, Kishimoto H, Osteoporosis Diagnostic Criteria Review Committee: Japanese Society for Bone and Mineral Research (2001) Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab 19:331–337CrossRefGoogle Scholar
  14. 14.
    Samson MM, Meeuwsen IBAE, Crowe A, Dessens JAG, Duursma SA, Verhaar HJJ (2010) Differences in variables of muscle strength and functional mobility in healthy subjects in relation to age, height and body weight. Age Ageing 29:235–242CrossRefGoogle Scholar
  15. 15.
    Kallman DA, Plato CC, Tobin JD (1990) The role of muscle loss in the age-related decline of grip strength: cross-sectional and longitudinal perspectives. J Gerontol 45:M82–M88CrossRefGoogle Scholar
  16. 16.
    Panotopoulos G, Raison J, Ruiz JC, Guy-Grand B, Basdevant A (1997) Weight gain at the time of menopause. Hum Reprod 12:126–133CrossRefGoogle Scholar
  17. 17.
    Guo SS, Zeller C, Chumlea WC, Siervogel RM (1999) Aging, body composition, and lifestyle: the Fels Longitudinal Study. Am J Clin Nutr 70:405–411CrossRefGoogle Scholar
  18. 18.
    Kyle UG, Genton L, Hans D, Karsegard VL, Michel JP, Slosman DO, Pichard C (2001) Total body mass, fat mass, fat-free mass, and skeletal muscle in older people: cross-sectional differences in 60-year-old persons. J Am Geriatr Soc 49:1633–1640CrossRefGoogle Scholar
  19. 19.
    Chumlea WC, Guo SS, Kuczmarski RJ, Flegal KM, Johnson CL, Heymsfield SB, Lukaski HC, Friedl K, Hubbard VS (2002) Body composition estimates from NHANES III bioelectrical impedance data. Int J Obes Relat Metab Disord 26:1596–1609CrossRefGoogle Scholar
  20. 20.
    Visser M, Pahor M, Tylavsky F, Kritchevsky SB, Cauley JA, Newman AB, Blunt BA, Harris TB (2003) One- and two-year change in body composition as measured by DXA in a population-based cohort of older men and women. J Appl Physiol 94:2368–2374CrossRefGoogle Scholar
  21. 21.
    Migliaccio S, Greco EA, Aversa A, Lenzi A (2014) Age-associated (cardio)metabolic diseases and cross-talk between adipose tissue and skeleton: endocrine aspects. Horm Mol Biol Clin Investig 20:25–38PubMedGoogle Scholar
  22. 22.
    Han TS, Wu FC, Lean ME (2013) Obesity and weight management in the elderly: a focus on men. Best Pract Res Clin Endocrinol Metab 27:509–525CrossRefGoogle Scholar
  23. 23.
    Gill LE, Bartels SJ, Batsis JA (2015) Weight management in older adults. Curr Obes Rep 4:379–388CrossRefGoogle Scholar
  24. 24.
    Launer LJ, Harris T, Rumpel C, Madans J (1994) Body mass index, weight change, and risk of mobility disability in middle-aged and older women. The epidemiologic follow-up study of NHANES I. JAMA 271:1093–1098CrossRefGoogle Scholar
  25. 25.
    Losonczy KG, Harris TB, Cornoni-Huntley J, Simonsick EM, Wallace RB, Cook NR, Ostfeld AM, Blazer DG (1995) Does weight loss from middle age to old age explain the inverse weight mortality relation in old age? Am J Epidemiol 141:312–321CrossRefGoogle Scholar
  26. 26.
    Fine JT, Colditz GA, Coakley EH, Moseley G, Manson JE, Willett WC, Kawachi I (1999) A prospective study of weight change and health-related quality of life in women. JAMA 282:2136–2142CrossRefGoogle Scholar
  27. 27.
    Newman AB, Yanez D, Harris T, Duxbury A, Enright PL, Fried LP, Cardiovascular Study Research Group (2001) Weight change in old age and its association with mortality. J Am Geriatr Soc 49:1309–1318CrossRefGoogle Scholar
  28. 28.
    Ensrud KE, Ewing SK, Taylor BC, Fink HA, Cawthon PM, Stone KL, Hillier TA, Cauley JA, Hochberg MC, Rodondi N, Tracy JK, Cummings SR (2008) Comparison of 2 frailty indexes for prediction of falls, disability, fractures, and death in older women. Arch Intern Med 168:382–389CrossRefGoogle Scholar
  29. 29.
    Ensrud KE, Ewing SK, Cawthon PM, Fink HA, Taylor BC, Cauley JA, Dam TT, Marshall LM, Orwoll ES, Cummings SR, Osteoporotic Fractures in Men Research Group (2009) A comparison of frailty indexes for the prediction of falls, disability, fractures, and mortality in older men. J Am Geriatr Soc 57:492–498CrossRefGoogle Scholar
  30. 30.
    Colón-Emeric CS, Mesenbrink P, Lyles KW, Pieper CF, Boonen S, Delmas P, Eriksen EF, Magaziner J (2010) Potential mediators of the mortality reduction with zoledronic acid after hip fracture. J Bone Miner Res 25:91–97CrossRefGoogle Scholar
  31. 31.
    Børsheim E, Herndon DN, Hawkins HK, Suman OE, Cotter M, Klein GL (2014) Pamidronate attenuates muscle loss after pediatric burn injury. J Bone Miner Res 29:1369–1372CrossRefGoogle Scholar
  32. 32.
    Park JH, Park KH, Cho S, Choi YS, Seo SK, Lee BS, Park HS (2013) Concomitant increase in muscle strength and bone mineral density with decreasing IL-6 levels after combination therapy with alendronate and calcitriol in postmenopausal women. Menopause 20:747–753CrossRefGoogle Scholar
  33. 33.
    Watanabe R, Fujita N, Takeda S, Sato Y, Kobayashi T, Morita M, Oike T, Miyamoto K, Matsumoto Y, Matsumoto M, Nakamura M, Miyamoto T (2017) Ibandronate concomitantly blocks immobilization-induced bone and muscle atrophy. Biochem Biophys Res Commun.  https://doi.org/10.1016/j.bbrc.2016.10.112 (epub ahead of print) CrossRefGoogle Scholar
  34. 34.
    Bandeira L, Bilezikian JP (2017) Novel therapies for postmenopausal osteoporosis. Endocrinol Metab Clin N Am 46:207–219CrossRefGoogle Scholar

Copyright information

© The Japanese Society for Bone and Mineral Research and Springer Japan KK, part of Springer Nature 2017

Authors and Affiliations

  • Tomohiko Urano
    • 1
    • 2
  • Masataka Shiraki
    • 3
  • Tatsuhiko Kuroda
    • 4
  • Shiro Tanaka
    • 5
  • Fumihiko Urano
    • 6
  • Kazuhiro Uenishi
    • 7
  • Satoshi Inoue
    • 1
    • 8
    • 9
  1. 1.Department of Geriatric Medicine, Graduate School of MedicineUniversity of TokyoTokyoJapan
  2. 2.Department of Geriatric Medicine, School of MedicineInternational University of Health and WelfareChibaJapan
  3. 3.Research Institute and Practice for Involutional DiseasesNaganoJapan
  4. 4.Public Health Research FoundationTokyoJapan
  5. 5.Department of Pharmacoepidemiology, Graduate School of Medicine and Public HealthKyoto UniversityKyotoJapan
  6. 6.Division of Endocrinology, Metabolism, and Lipid Research, Department of MedicineWashington University School of MedicineSt. LouisUSA
  7. 7.Division of Nutritional PhysiologyKagawa Nutrition UniversitySaitamaJapan
  8. 8.Department of Functional BiogerontologyTokyo Metropolitan Institute of GerontologyTokyoJapan
  9. 9.Research Center for Genomic MedicineSaitama Medical SchoolSaitamaJapan

Personalised recommendations